clopidogrel
Plavix (clopidogrel) is a P2Y12 platelet inhibitor from Sanofi that prevents platelets from clumping into clots. It reduces the risk of heart attack and stroke after acute coronary syndromes, recent myocardial infarction, recent stroke, or established peripheral arterial disease.
This page is based on FDA prescribing information and the EMA medicine record for clopidogrel, cross-checked with MedlinePlus and the National Cancer Institute drug dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Platelets are the body's first responders, rushing to plug any leak by clumping together. After a heart attack or a stent, that clumping instinct can seal an artery instead of a wound. Clopidogrel permanently disables the rallying signal, the P2Y12 receptor, on each platelet it touches, so new clots are much less likely to form.
In simple terms
Clopidogrel belongs to the antiplatelet class. After it is taken by mouth, the body converts it into an active form that permanently blocks the P2Y12 receptor on platelets. With the receptor blocked, platelets are less able to collect and form the clots that can block arteries and cause a heart attack or stroke. Because each platelet is affected for life, the effect lasts as long as the platelet circulates.
In depth
Clopidogrel is a thienopyridine prodrug whose active metabolite irreversibly binds the P2Y12 adenosine diphosphate receptor on platelets, inhibiting ADP-mediated activation of the glycoprotein GPIIb/IIIa complex and preventing fibrinogen binding, platelet adhesion, and aggregation. This results in increased bleeding time and reduced atherothrombotic events. Indications cover secondary prevention after myocardial infarction, ischaemic stroke, or peripheral arterial disease, acute coronary syndromes in combination with aspirin, and, in the European Union, prevention of thromboembolic events in atrial fibrillation when vitamin K antagonists are unsuitable.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How clopidogrel, a P2Y12 platelet inhibitor, works
- Platelets are the body's first responders, rushing to plug any leak by clumping together.
- Clopidogrel permanently disables the rallying signal, the P2Y12 receptor, on each platelet it touches, so new clots are much less likely to form.
- Clopidogrel is a thienopyridine prodrug whose active metabolite irreversibly binds the P2Y12 adenosine diphosphate receptor on platelets, inhibiting ADP-mediated activation of the glycoprotein GPIIb/IIIa complex and preventing fibrinogen binding, platelet adhesion, and aggregation.
- Because each platelet is affected for life, the effect lasts as long as the platelet circulates.
Target: P2Y12 receptor on platelets
A platelet surface receptor that amplifies platelet activation and clumping when adenosine diphosphate binds; irreversibly blocking it keeps platelets from collecting into the clots that cause heart attacks and strokes.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the rate of myocardial infarction and stroke in patients with non-ST-segment elevation acute coronary syndrome (unstable angina or non-ST-elevation myocardial infarction), including patients managed medically and those managed with coronary revascularization, in conjunction with aspirin
- To reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction managed medically, in conjunction with aspirin
- To reduce the rate of myocardial infarction and stroke in patients with established peripheral arterial disease or with a history of recent myocardial infarction or recent stroke
Approved uses in European Union
EMA- Secondary prevention of atherothrombotic events in adult patients with myocardial infarction, ischaemic stroke, or established peripheral arterial disease
- Adult patients with acute coronary syndrome, including those undergoing stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid
- In combination with acetylsalicylic acid, for adult patients with moderate to high-risk transient ischaemic attack or minor ischaemic stroke within 24 hours of the event
- In combination with acetylsalicylic acid, for prevention of atherothrombotic and thromboembolic events in adult patients with atrial fibrillation who have at least one risk factor for vascular events and are not suitable for vitamin K antagonists
Official sources
The statements on this page trace back to these records.
- U.S. Food and Drug Administration: clopidogrel prescribing information
U.S. Food and Drug Administration
- Iscover (clopidogrel) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- MedlinePlus: clopidogrel
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: clopidogrel
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.